Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C107671-10mg | 10mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $130.90 | |
C107671-20mg | 20mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $237.90 | |
C107671-50mg | 50mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $1,241.90 |
Synonyms | celastrol|34157-83-0|Tripterin|Tripterine|(2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid|NSC70931|(2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9, |
---|---|
Specifications & Purity | analytical standard,≥98% |
Storage Temp | Store at -20°C |
Shipped In | Dry ice |
Grade | analytical standard, Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of regulator of G-protein signaling 17 |
Product Description | Celastrol, Celastrus scandens, a compound originally purified from Tripterygium wilfordii, has been shown to be an anti-peroxidative and anti-angiogenic agent. Mechanistic studies suggest that Celastrol suppresses levels of VEGF and Flk-1 receptors, VEGFR-1 and VEGFR-2, which may reduce signal transduction between the two growth factors. Additionally, Celastrol has demonstrated the ability to disrupt critical interaction of Glu33 (Hsp90) and Arg167 (Cdc37) in the superchaperone complex which causes anti-proliferative activity in vitro and inhibit Topo II (topoisomerase II) activity in vitro (IC50 = 7.41 μM). Celastrol, Celastrus scandens is an inhibitor of Hsp90. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid |
---|---|
INCHI | InChI=1S/C29H38O4/c1-17-18-7-8-21-27(4,19(18)15-20(30)23(17)31)12-14-29(6)22-16-26(3,24(32)33)10-9-25(22,2)11-13-28(21,29)5/h7-8,15,22,31H,9-14,16H2,1-6H3,(H,32,33)/t22-,25-,26-,27+,28-,29+/m1/s1 |
InChi Key | KQJSQWZMSAGSHN-JJWQIEBTSA-N |
Canonical SMILES | CC1=C(C(=O)C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C)O |
Isomeric SMILES | CC1=C(C(=O)C=C2C1=CC=C3[C@]2(CC[C@@]4([C@@]3(CC[C@@]5([C@H]4C[C@](CC5)(C)C(=O)O)C)C)C)C)O |
WGK Germany | 2 |
Alternate CAS | 34157-83-0 |
PubChem CID | 122724 |
NSC Number | 70931 |
UN Number | 2811 |
MeSH Entry Terms | 3-hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic acid;celastrol;tripterin;tripterine |
Molecular Weight | 450.61 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
I2116200 | Certificate of Analysis | Jun 14, 2023 | C107671 |
C2218431 | Certificate of Analysis | Mar 24, 2022 | C107671 |
C2218450 | Certificate of Analysis | Mar 24, 2022 | C107671 |
Solubility | Soluble in DMSO (>10 mg/ml), ethanol, DMF:PBS(pH 7.2)(1:10), and DMF. Insoluble in water. |
---|---|
Specific Rotation[α] | -122.7° (C=0.1,CHCl3) |
Melt Point(°C) | 203°C(lit.) |
Pictogram(s) | GHS06 |
---|---|
Signal | Danger |
Hazard Statements | H301:Toxic if swallowed |
Precautionary Statements | P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P316:IF SWALLOWED: Get emergency medical help immediately. |
WGK Germany | 2 |
1. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C. (2001) Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease.. Prog Neuropsychopharmacol Biol Psychiatry, 25 (7): (1341-57). [PMID:11513350] |
2. Pfuhlmann K, Schriever SC, Baumann P, Kabra DG, Harrison L, Mazibuko-Mbeje SE, Contreras RE, Kyriakou E, Simonds SE, Tiganis T et al.. (2018) Celastrol-Induced Weight Loss Is Driven by Hypophagia and Independent From UCP1.. Diabetes, 67 (11): (2456-2465). [PMID:30158241] |
3. Zhan X, Yan C, Chen Y, Wei X, Xiao J, Deng L, Yang Y, Qiu P, Chen Q. (2018) Celastrol antagonizes high glucose-evoked podocyte injury, inflammation and insulin resistance by restoring the HO-1-mediated autophagy pathway.. Mol Immunol, 104 (3): (61-68). [PMID:30439604] |
4. Wong VKW, Qiu C, Xu SW, Law BYK, Zeng W, Wang H, Michelangeli F, Dias IRSR, Qu YQ, Chan TW et al.. (2019) Ca2+ signalling plays a role in celastrol-mediated suppression of synovial fibroblasts of rheumatoid arthritis patients and experimental arthritis in rats.. Br J Pharmacol, 176 (16): (2922-2944). [PMID:31124139] |
5. Shi K, Chen X, Xie B, Yang SS, Liu D, Dai G, Chen Q. (2018) Celastrol Alleviates Chronic Obstructive Pulmonary Disease by Inhibiting Cellular Inflammation Induced by Cigarette Smoke via the Ednrb/Kng1 Signaling Pathway.. Front Pharmacol, 9 (3): (1276). [PMID:30498444] |
6. Zhang J, Zhou K, Zhang X, Zhou Y, Li Z, Shang F. (2019) Celastrol Ameliorates Inflammation in Human Retinal Pigment Epithelial Cells by Suppressing NF-κB Signaling.. J Ocul Pharmacol Ther, 35 (2): (116-123). [PMID:30596540] |
7. Zhou X, Cao X, Tu H, Zhang ZR, Deng L. (2019) Inflammation-Targeted Delivery of Celastrol via Neutrophil Membrane-Coated Nanoparticles in the Management of Acute Pancreatitis.. Mol Pharm, 16 (3): (1397-1405). [PMID:30753778] |
8. Venkatesha SH, Moudgil KD. (2019) Celastrol suppresses experimental autoimmune encephalomyelitis via MAPK/SGK1-regulated mediators of autoimmune pathology.. Inflamm Res, 68 (4): (285-296). [PMID:30820608] |
9. Feng X, Guan D, Auen T, Choi JW, Salazar Hernández MA, Lee J, Chun H, Faruk F, Kaplun E, Herbert Z et al.. (2019) IL1R1 is required for celastrol's leptin-sensitization and antiobesity effects.. Nat Med, 25 (4): (575-582). [PMID:30833749] |